Practice Signal
This review helps pharmacists distinguish practice-changing checkpoint inhibitor regimens from hypothesis-generating signals and anticipate the toxicity patterns that follow the chemotherapy backbone versus the immune component.
PD-1/PD-L1 checkpoint inhibitors have moved from metastatic salvage to validated first-line and adjuvant use across GI and liver cancers, but the strength of evidence and the role of the chemotherapy backbone differ sharply by tumor type and treatment setting.
Immune checkpoint inhibition is now embedded in first-line care for advanced cholangiocarcinoma and in adjuvant care for deficient mismatch repair (dMMR) stage III colon cancer, while its role after curative hepatocellular carcinoma (HCC) resection remains investigational. Across settings the recurring theme is that most severe toxicity tracks with the cytotoxic backbone, whereas immune-related adverse events (irAEs) accumulate during checkpoint inhibitor exposure.
The ATOMIC trial (atezolizumab plus mFOLFOX6) delivered a roughly 50% relative reduction in recurrence or death in resected dMMR stage III colon cancer, a high-grade practice-changing result already incorporated into National Comprehensive Cancer Network (NCCN) guidance. In cholangiocarcinoma, TOPAZ-1 and KEYNOTE-966 confirmed chemo-immunotherapy as first-line standard, while an observational HCC analysis suggesting comparable benefit from adjuvant transarterial chemoembolization (TACE) versus adjuvant lenvatinib plus tislelizumab remains hypothesis-generating.
The cholangiocarcinoma first-line data align cleanly with current NCCN and European Society for Medical Oncology (ESMO) hepatobiliary guidance, which list durvalumab plus gemcitabine-cisplatin (GemCis) and pembrolizumab plus GemCis as preferred options. The ATOMIC findings reinforce NCCN Colon Cancer guidance (Version 2.2025) and universal mismatch repair testing, whereas no major guideline (NCCN Hepatobiliary, European Association for the Study of the Liver [EASL]) yet endorses a single adjuvant HCC standard, leaving the observational lenvatinib-tislelizumab and TACE data ahead of formal recommendation.
| Source | Key finding | Grade / Verdict |
|---|---|---|
|
Adjuvant TACE and Lenvatinib-Tislelizumab Show Comparable Post-Resection Benefit
Study · Frontiers in Immunology
hypothesis-generating adjuvant HCC signal Observational data suggest both adjuvant TACE and adjuvant lenvatinib-tislelizumab reduce recurrence and death after HCC resection, without demonstrating superiority between them.
|
Adjuvant lenvatinib plus tislelizumab reduced recurrence risk, HR 0.214, 95% CI 0.144–0.320 | Grade: Low Hypothesis-generating |
|
Immune Checkpoint Inhibitors Redefine First-Line Cholangiocarcinoma Therapy
Study · Journal of the Egyptian National Cancer Institute
confirmatory first-line standard Confirms durvalumab or pembrolizumab plus GemCis as validated first-line therapy for advanced cholangiocarcinoma while relegating triplet and biomarker strategies to investigational status.
|
Durvalumab plus GemCis improved median OS to 12.9 versus 11.3 months, HR 0.76, 95% CI 0.64–0.91 | Grade: Moderate Confirmatory |
|
Atezolizumab Plus FOLFOX Halves Recurrence in dMMR Stage III Colon Cancer
Study · N Engl J Med
new pillar adjuvant evidence Establishes adjuvant atezolizumab plus mFOLFOX6 as practice-changing for resected dMMR stage III colon cancer, already reflected in NCCN guidance.
|
Atezolizumab plus mFOLFOX6 cut recurrence or death, HR 0.50, 95% CI 0.35–0.73 | Grade: High Practice-changing |
Subscribe to PharmD Signal for the complete practice recommendations on every topic, plus every deep analysis we publish.
Become a Subscriber →